ABSTRACT -Since malignant tumors are life-threatening, the death rate from these diseases is high, -including regulatory, academic and industrial scientists to prepare the guideline on the non-clinical safety -Key words:
INTRODUCTION
For the test methods of non-clinical safety studies required for applications for approval to manufacture (import) drugs, various guidelines for test methods including "Guidelines for Toxicity Studies of Drugs" (Guideline for Toxicity Studies; MHW, 1989) have been published, and for the timing of non-clinical studies, "Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals" (M3 Guideline; MHW, 1998) specbeen developed, including those that directly or indirectly is called cytotoxicity, those that selectively block moleblood vessels required for proliferation of malignancy, and those that are highly selective because of their molecexisting non-clinical safety studies may not adequately examine high dose exposure over the clinical dosage -achieve the goal of the studies), or because of the severity of indicated disease, the therapeutic dosage and observed adverse reaction dose level may be close to each other, and for the social responsibility for providing patients clinical safety studies are currently conducted on a case--cept, and because of these agents' clinical particularity that they are administered to patients from Phase I clinical trials, the study items and study contents may be inappropriate due to the varied concept of applicants, or the timing of study conduct may be inappropriate, and thus aiming for more appropriate safety evaluations are conduced at the appropriate time, as a guide for basic concept of non-clinical safety studies on anticancer drugs, "Points to consider on non-clinical safety evaluation of anticancer conducted for clinical trails and approval applications for
The objective of this "Points to Consider" is to minimize the risk of patients, and to promote the development of anticancer drugs by presenting the basic concept of non-clinical safety studies required prior to the initiation of Phase I clinical trials and approval applications for 
Single dose toxicity studies
Single-dose toxicity studies should be conducted in least one animal species, female and male animals should be studied, and approximate lethal dose should also be --er, if the clinical route of administration in humans cannot deliver adequate exposure, the route of administration
Repeated dose toxicity studies
The schedule of administration (repeated administration or intermittent administration, intervals for intermit- 
Repeated dose toxicity studies should be conducted in only male or female patients demonstrated no apparent sex difference in short-term repeated dose toxicity studies -ics suggested no sex difference, long-term repeated dose toxicity studies may be conducted in the sex that is sub-(daily administration or intermittent administration, intervals for intermittent administration) for the repeated dose toxicity studies should be chosen, taking the pharmacological, pharmacokinetic characteristics of the drug, the --months in non-rodents as a rule, but considering the toxicological characteristics of the anticancer drug and duration of treatment in clinical practice, setting a more approdesigned so as to either one of the studies can examine 2. Genotoxicity studies -anism of action and so on, the standard battery of genoto-
Carcinogenicity studies
See "Guidance on genotoxicity tests of pharmaceuticals"
Reproductive and developmental toxicity studies
has been suggested to have an embryonic lethality or teratogenicity, the reproductive and developmental toxicity In these cases, pregnant female patients, nursing mother are contraindicated, and female patients of childbearing potential and male patients are instructed to practice strict When the reproductive and developmental toxicity, especially teratogenicity is to be examined, because of the nature of the drug such as potent maternal toxicity or embryonic lethality, the duration of administration or intervals varied from those specified in "Guidelines Supplemental data are available at the on-line version
